CTLA4 and melanoma: A study demonstrated that increased expression of PD-L1, post-azacitidine treatment, elevated the anti-PD1 therapy response, while in melanoma, lower CTLA-4 methylation resulted in a better response to anti-CTLA-4 or PD1 therapy [103, 104].